Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
about
Role of systemic chemotherapy in urothelial urinary bladder cancerSurgical resection of urological tumor metastases following medical treatmentTime from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trialsPaclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis.Systemic therapy for bladder cancer - a medical oncologist's perspective.First- and second-line therapy for metastatic urothelial carcinoma of the bladderNovel agents for advanced bladder cancer.Current therapeutic strategies for invasive and metastatic bladder cancer.Chemotherapy in advanced bladder cancer: current status and futureCisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapyEpicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapyUse of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer.Urothelial carcinoma management in elderly or unfit patients.Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial CarcinomaPotential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Urothelial carcinoma of the bladder: definition, treatment and future efforts.Current treatment of metastatic bladder cancer and future directions.Urothelial cancers: using biology to improve outcomes.Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.A Case of Metastatic Urothelial Carcinoma Treated with Pemetrexed as Third-Line Chemotherapy with Discussion and Literature Review.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors.Establishment and characterization of a bladder cancer cell line with enhanced doxorubicin resistance by mevalonate pathway activation.Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaVinflunine in the treatment of bladder cancer.[Systemic therapy of metastatic bladder cancer.]A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy.A phase II trial of temsirolimus in second-line metastatic urothelial cancer.
P2860
Q27010323-C560B047-0BE0-493F-8826-24A4ECB27BD2Q27013035-5D79848B-0AC6-45F7-8E9F-D2E1651C3263Q28280571-FDC18C27-687C-4146-BE98-1A5E6CC7E0F2Q33403679-02E72F71-3BFD-4C24-AB10-1BA5DE4CA4A0Q33408261-2A0BF3DD-A254-4FFE-846F-FA11E81DCD4DQ33431220-40595584-B12A-42AC-ADC1-7E560E101968Q34516731-4D9CD7D1-CCEF-4CA9-A770-93D4B03B8F8AQ34541463-90730FEA-1362-4248-8F79-12782192FADDQ35076184-DEDC564B-C617-4BD1-BADB-E43EB610525EQ35128721-B1924EE7-44C6-451F-9FE3-08CE07D11E47Q35227771-46D8417C-5E4D-437F-9B9F-177AFEBF024CQ35771672-28A17E8B-5282-4ABC-AF72-27F318DBCE75Q36143699-9EE2C2A7-1DFE-4046-AD83-F681C8367B57Q36192053-A27B9F27-4616-4FB2-9CE1-77743EE4E5E7Q36421012-5F85031A-D252-4635-94AA-72EC0BC7F547Q36627206-7FA12D92-FFE5-4F51-B707-CD9B467AE8F6Q36953789-D121088F-9CEB-437E-8D58-350EF60D4C9DQ37030514-007C1DC1-1D46-4964-A14C-5C904FF6157AQ37261102-89B153AE-7F6F-4952-8C8D-3E180E8D908BQ37393594-FD041AF4-446C-408A-AC05-C92B8E4CC1AAQ37514607-BFA72FF7-8757-4215-969B-6070EC9242E1Q37702430-1CECC5AE-61AA-458C-BAE6-529822938DE2Q37944437-A9207DB6-9209-41B0-93AE-1373D35ED1C7Q37960909-C6D2BE38-4FC3-4071-9273-12A906DBE64EQ37965638-D874284C-6937-4EF0-A395-01969FDDC2C9Q38155201-799F0EB8-1D13-4853-AB1E-E6EE80306AA9Q38312045-E0AE0D6F-1C2B-4DFD-A9BD-EBBC8B35B83AQ38457425-00723BCA-57FC-4A75-B739-8E71E250A0B0Q38612831-E3414CCD-CCA2-4BBA-BB63-A290CD762E8FQ38669606-E510BDE7-D91D-4BF5-9307-C3C72675D018Q38701535-DEDC15D7-4600-494A-9370-1F282C31B7D3Q38798645-7193BB2D-0485-4B55-854F-E6847E45B663Q38865758-A6559E2B-C527-4F38-8AD7-8A9E6C724EA5Q38922396-FFBCB414-2C17-428F-99CE-1163C474DD1AQ41768357-8D727CB3-5D20-4C16-898B-A3F35049E0B3Q42183149-D3488B1A-6592-4FF0-98C3-BC54F5BBAEFBQ44419809-11D9BCB8-7D1F-4952-8326-27961A0808BFQ46311055-4F51EADC-E972-4CAD-BC47-B82859C8DA75Q47102176-225E341A-093C-4F29-8C21-074083F7FE64Q48463573-B61328E3-240B-4811-92CF-B18B3A53A9E2
P2860
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Randomized phase III trial of ...... ncology (AUO) trial AB 20/99].
@en
Randomized phase III trial of ...... ciation of Urological Oncology
@nl
type
label
Randomized phase III trial of ...... ncology (AUO) trial AB 20/99].
@en
Randomized phase III trial of ...... ciation of Urological Oncology
@nl
prefLabel
Randomized phase III trial of ...... ncology (AUO) trial AB 20/99].
@en
Randomized phase III trial of ...... ciation of Urological Oncology
@nl
P2093
P2860
P921
P356
P1433
P1476
Randomized phase III trial of ...... ncology (AUO) trial AB 20/99].
@en
P2093
A Heidenreich
AUO Bladder Cancer Group
D Heimbach
P2860
P304
P356
10.1093/ANNONC/MDQ398
P577
2010-08-02T00:00:00Z